Compare PDEX & PEPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PDEX | PEPG |
|---|---|---|
| Founded | 1978 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.4M | 207.1M |
| IPO Year | 1995 | 2022 |
| Metric | PDEX | PEPG |
|---|---|---|
| Price | $72.89 | $2.91 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $56.00 | $11.17 |
| AVG Volume (30 Days) | 62.5K | ★ 613.9K |
| Earning Date | 05-01-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.31 | 25.61 |
| EPS | ★ 4.12 | N/A |
| Revenue | ★ $77,548,000.00 | N/A |
| Revenue This Year | $7.22 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.60 | ★ N/A |
| Revenue Growth | ★ 16.45 | N/A |
| 52 Week Low | $23.52 | $1.31 |
| 52 Week High | $77.00 | $7.80 |
| Indicator | PDEX | PEPG |
|---|---|---|
| Relative Strength Index (RSI) | 60.59 | 48.47 |
| Support Level | $56.35 | $1.60 |
| Resistance Level | $77.00 | $3.14 |
| Average True Range (ATR) | 4.29 | 0.17 |
| MACD | 0.90 | -0.06 |
| Stochastic Oscillator | 78.30 | 11.76 |
Pro-Dex Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers (OEMs) to various countries. Its product portfolio includes autoclavable, battery-powered, electric, and multi-function surgical drivers and shavers used mainly in orthopedic, thoracic, and craniomaxillofacial markets. The company also provides engineering, quality, regulatory consulting services, and manufactures rotary air motors utilized in various industries. Operating out of ISO-certified facilities in California, Pro-Dex serves hospitals, medical labs, and high-tech manufacturers, generating revenue through sales of surgical instruments and related services.
PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics to transform the treatment of severe neuromuscular and neurologic diseases. The company has developed its Enhanced Delivery Oligonucleotide platform to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake, and nuclear delivery, and in preclinical studies, it is observed that their ability to transport oligonucleotides into a broad range of target tissues, including smooth, skeletal, and cardiac muscle, and the central nervous system. Its pipeline products are: PGN-EDO51, PGN-EDODM1, and others.